AVREND

Pharmaceuticals, namely, pharmaceutical for use in treating paraneoplastic and neoplastic diseases and cancer, pharmaceuticals for use as prophylaxis or treatment of infectious diseases, pharmaceuticals for use as adjuvant to vaccination, pharmaceuticals for use in activating or expanding cell populations in ex vivo settings or processes, pharmaceuticals for use in the treatment of immune diseases and immune deficiencies, and pharmaceuticals for use in treatment of bone diseases and disorders